Zoetis Inc.
NYSE:ZTSDrug Manufacturers - General
+$1.17 today
- Market cap
- $34.76B
- Beta
- 0.74
- P/E (TTM)
- 12.5
- EPS (TTM)
- $6.26
- Dividend yield
- 2.63%
Volume 4.66M
Average 6.20M
ZTS Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Zoetis Inc.NYSE: ZTS
Accounts Receivables · Q2 FY2026 · quarter ended Jun 2026
Accounts receivables dips below year-ago levels
Q2 FY2026 accounts receivables of $66M (cash outflow) fell 53.2% year over year, behind the +49.7% change in trailing-twelve-month accounts receivables. Sequentially, it fell 37.7% from the prior quarter. Over 3 fiscal years it compounded at +19.9% a year.
Context
- Accounts receivables amounted to 2.5% of revenue in FY2025, up 1.8 pp from a year earlier.
- Accounts receivables grew in size in 1 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -53.2% toward the trailing-twelve-month pace of +49.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (236M) USD
- Year-over-year change
- -286.9%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (236M) | -286.9% |
| FY2024 | 2024-12-31 | (61M) | +40.2% |
| FY2023 | 2023-12-31 | (102M) | +25.5% |
| FY2022 | 2022-12-31 | (137M) | +11.6% |
| FY2021 | 2021-12-31 | (155M) | — |
Accounts Receivables vs competitors
How ZTS compares with its peers on the latest reported figures
- ZTS's LTM Jun 2026 accounts receivables of $214M is the 2nd largest of the 6 companies compared; the peer median is $17.03M.
- Its year-over-year change of +49.7% is the highest of 5, against a peer median of -100.8%.
- Accounts receivables amounts to 2.2% of revenue for ZTS, versus a peer median of 1.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.09B | — | +19.2% | 1.6% | |
| LTM Jun 2026 | $214M | +49.7% | +19.9% | 2.2% | |
| LTM Sep 2026 | $58.9M | -311.8% | +18.4% | 1.3% | |
| LTM Mar 2026 | $17.03M | -58.4% | +32.7% | 1.1% | |
| LTM Aug 2026 | $407K | -101.7% | — | 0.0% | |
| LTM Sep 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding ZTS) | $17.03M | -100.8% | +19.2% | 1.1% | |
Competitors are the stored peer set for ZTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 2.03B | 2.11B | 2.34B | 2.5B | 2.67B |
| Depreciation & Amortization | 448M | 465M | 491M | 497M | 487M |
| Deferred Income Tax | (80M) | (286M) | (61M) | (338M) | (52M) |
| Stock-Based Compensation | 58M | 62M | 60M | 74M | 83M |
| Change in Working Capital | (343M) | (699M) | (512M) | 79M | (408M) |
| Accounts Receivables | (155M) | (137M) | (102M) | (61M) | (236M) |
| Inventory | (366M) | (486M) | (361M) | (40M) | (199M) |
| Accounts Payables | (17M) | (29M) | 13M | 31M | 46M |
| Other Working Capital | 195M | (47M) | (62M) | 149M | (19M) |
| Other Non-Cash Items | 96M | 259M | 31M | 145M | 121M |
| Operating Cash Flow | 2.21B | 1.91B | 2.35B | 2.95B | 2.9B |
| Capital Expenditures | (477M) | (586M) | (732M) | (655M) | (621M) |
| Acquisitions (Net) | (14M) | (312M) | (59M) | 285M | (24M) |
| Purchases of Investments | (12M) | (9M) | (4M) | (5M) | (7M) |
| Sales of Investments | 44M | 23M | 12M | 62M | 0 |
| Other Investing Activities | 1M | 1M | 6M | (2M) | (96M) |
| Investing Cash Flow | (458M) | (883M) | (777M) | (315M) | (748M) |
| Debt Repayment | (604M) | 1.35B | (1.35B) | (3M) | 2.27B |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | (743M) | (1.59B) | (1.09B) | (1.86B) | (3.24B) |
| Dividends Paid | (474M) | (611M) | (692M) | (786M) | (889M) |
| Other Financing Activities | (45M) | (49M) | 24M | (13M) | (14M) |
| Financing Cash Flow | (1.86B) | (904M) | (3.11B) | (2.66B) | (1.87B) |
| Effect of Forex Changes | (12M) | (29M) | (7M) | (32M) | 39M |
| Net Change in Cash | (119M) | 96M | (1.54B) | (54M) | 325M |
| Free Cash Flow | 1.74B | 1.33B | 1.62B | 2.3B | 2.28B |
Zoetis Inc.
NYSE:ZTS
Intrinsic Alpha fair value
Locked
Current Price
$85.55
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.